MX2023004089A - Métodos para el tratamiento del cáncer con conjugados de fármaco y anticuerpos (adc) que se unen a las proteínas 191p4d12. - Google Patents
Métodos para el tratamiento del cáncer con conjugados de fármaco y anticuerpos (adc) que se unen a las proteínas 191p4d12.Info
- Publication number
- MX2023004089A MX2023004089A MX2023004089A MX2023004089A MX2023004089A MX 2023004089 A MX2023004089 A MX 2023004089A MX 2023004089 A MX2023004089 A MX 2023004089A MX 2023004089 A MX2023004089 A MX 2023004089A MX 2023004089 A MX2023004089 A MX 2023004089A
- Authority
- MX
- Mexico
- Prior art keywords
- adc
- bind
- methods
- proteins
- drug conjugates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Physiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063090272P | 2020-10-11 | 2020-10-11 | |
| US202163148038P | 2021-02-10 | 2021-02-10 | |
| US202163193493P | 2021-05-26 | 2021-05-26 | |
| PCT/US2021/054084 WO2022076767A1 (en) | 2020-10-11 | 2021-10-08 | Methods for treating cancers with antibody drug conjugates (adc) that bind to 191p4d12 proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023004089A true MX2023004089A (es) | 2023-06-28 |
Family
ID=81125466
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023004089A MX2023004089A (es) | 2020-10-11 | 2021-10-08 | Métodos para el tratamiento del cáncer con conjugados de fármaco y anticuerpos (adc) que se unen a las proteínas 191p4d12. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230364254A1 (https=) |
| EP (1) | EP4225379A4 (https=) |
| JP (1) | JP2023545432A (https=) |
| KR (1) | KR20230106607A (https=) |
| AU (1) | AU2021356542A1 (https=) |
| CA (1) | CA3198359A1 (https=) |
| IL (1) | IL302006A (https=) |
| MX (1) | MX2023004089A (https=) |
| TW (1) | TW202228788A (https=) |
| WO (1) | WO2022076767A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019392090A1 (en) | 2018-12-03 | 2021-06-17 | Agensys, Inc. | Pharmaceutical compositions comprising anti-191P4D12 antibody drug conjugates and methods of use thereof |
| WO2024012541A1 (zh) * | 2022-07-14 | 2024-01-18 | 百奥泰生物制药股份有限公司 | 抗Nectin-4抗体药物偶联物及应用 |
| WO2024012536A1 (zh) * | 2022-07-14 | 2024-01-18 | 百奥泰生物制药股份有限公司 | 抗Nectin-4抗体、其抗体药物偶联物及应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX347954B (es) * | 2010-09-29 | 2017-05-19 | Agensys Inc | Conjugados de anticuerpo farmaco (adc) que enlazan a proteinas 191p4d12. |
| AU2019342099A1 (en) * | 2018-09-19 | 2021-04-08 | Genentech, Inc. | Therapeutic and diagnostic methods for bladder cancer |
| AU2019392090A1 (en) * | 2018-12-03 | 2021-06-17 | Agensys, Inc. | Pharmaceutical compositions comprising anti-191P4D12 antibody drug conjugates and methods of use thereof |
| AU2020241963A1 (en) * | 2019-03-17 | 2021-11-04 | Vasgene Therapeutics Inc | Treatment of cancers using sEphB4-HSA fusion proteins |
| TW202540197A (zh) * | 2019-08-13 | 2025-10-16 | 美商艾澤西公司 | 以結合191p4d12蛋白質之抗體藥物結合物(adc)治療癌症 |
| KR20230091885A (ko) * | 2020-09-17 | 2023-06-23 | 어젠시스 인코포레이티드 | 191p4d12 단백질에 결합하는 항체 약물 접합체(adc)로 암을 치료하는 방법 |
-
2021
- 2021-10-08 IL IL302006A patent/IL302006A/en unknown
- 2021-10-08 WO PCT/US2021/054084 patent/WO2022076767A1/en not_active Ceased
- 2021-10-08 US US18/030,225 patent/US20230364254A1/en active Pending
- 2021-10-08 CA CA3198359A patent/CA3198359A1/en active Pending
- 2021-10-08 KR KR1020237015737A patent/KR20230106607A/ko active Pending
- 2021-10-08 MX MX2023004089A patent/MX2023004089A/es unknown
- 2021-10-08 TW TW110137596A patent/TW202228788A/zh unknown
- 2021-10-08 JP JP2023521682A patent/JP2023545432A/ja active Pending
- 2021-10-08 EP EP21878582.2A patent/EP4225379A4/en active Pending
- 2021-10-08 AU AU2021356542A patent/AU2021356542A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202228788A (zh) | 2022-08-01 |
| WO2022076767A1 (en) | 2022-04-14 |
| US20230364254A1 (en) | 2023-11-16 |
| EP4225379A1 (en) | 2023-08-16 |
| AU2021356542A9 (en) | 2024-05-23 |
| KR20230106607A (ko) | 2023-07-13 |
| JP2023545432A (ja) | 2023-10-30 |
| AU2021356542A1 (en) | 2023-05-25 |
| CA3198359A1 (en) | 2022-04-14 |
| EP4225379A4 (en) | 2025-11-19 |
| IL302006A (en) | 2023-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12022550318A1 (en) | Treatment of cancers with antibody drug conjugates (adc) that bind to 191p4d12 proteins | |
| MX2023004089A (es) | Métodos para el tratamiento del cáncer con conjugados de fármaco y anticuerpos (adc) que se unen a las proteínas 191p4d12. | |
| CL2020003071A1 (es) | Proteínas de unión multiespecíficas y mejoras con estas | |
| PH12022551098A1 (en) | Treatment of cancers with antibody drug conjugates (adc) that bind to 191p4d12 proteins | |
| MX2024011292A (es) | Conjugados de camptotecina. | |
| TW201713360A (en) | Methods of treating cancer using compositions of antibodies and carrier proteins | |
| CY1121023T1 (el) | Συζευγματα αντισωματος φαρμακου (adc) τα οποια δεσμευονται σε 191p4d12 πρωτεϊνες | |
| CY1123525T1 (el) | Μορια δεσμευσης ειδικα για asct2 και χρησεις αυτων | |
| DOP2012000052A (es) | Proteínas terapéuticas de unión a dll4 | |
| CO6612264A2 (es) | Proteinas terapeuticas de la union a dll 4 | |
| EA201391449A1 (ru) | Антитела против пептидов цитозоля | |
| EA202090387A1 (ru) | Белки, связывающие nkg2d, cd16 и flt3 | |
| EA201600190A1 (ru) | Анти-prlr антитела и их применение | |
| PH12023550745A1 (en) | Methods for treating cancers with antibody drug conjugates (adc) that bind to 191p4d12 proteins | |
| PH12020551968A1 (en) | Anti-sez6 antibody drug conjugates and methods of use | |
| WO2023133388A3 (en) | Methods for treating muscle invasive urothelial cancer or muscle invasive bladder cancer with antibody drug conjugates (adc) that bind to 191p4d12 proteins | |
| AU2021344976A9 (en) | Methods for treating cancers with antibody drug conjugates (adc) that bind to 191p4d12 proteins | |
| MX2025004353A (es) | Construcciones de proteinas de union a lrrc15 y usos de estas | |
| PH12022553333A1 (en) | Markers for use in methods for treating cancers with antibody drug conjugates (adc) | |
| WO2022183112A3 (en) | Compositions and methods comprising antibodies that bind to covalent peptide conjugates | |
| MX2024001834A (es) | Metodos para tratar el cancer de vejiga no muscular invasivo (nmibc) con conjugados de anticuerpos y farmacos (adc) que se unen a las proteinas 191p4d12. | |
| MX2025000819A (es) | Metodos para el tratamiento de pacientes con cancer urotelial localmente avanzado o metastasico con conjugados de anticuerpo-farmaco (adc) que se unen a las proteinas 191p4d12 en combinacion con pembrolizumab | |
| MX2024001363A (es) | Metodos para el tratamiento de la leucemia mieloide aguda con los anticuerpos anti-ilt3. | |
| HK40095645A (en) | Methods for treating cancers with antibody drug conjugates (adc) that bind to 191p4d12 proteins | |
| HK40094115A (en) | Methods for treating cancers with antibody drug conjugates (adc) that bind to 191p4d12 proteins |